The Ultimate Non-Invasive Molecular War Plan
Comprehensive Genomic Profiling — 523 Genes from a Simple Blood Draw
When standard treatments stop working, or when you refuse to settle for routine care from day one, your treatment strategy must evolve. Signature Complete CGP is our most advanced, comprehensive blood-based somatic genomic test. By performing a high-precision multi-biomarker liquid biopsy, we extract circulating tumour DNA (ctDNA) from a simple blood sample to detect critical alterations across 523 genes with ultra-high sensitivity and specificity.
Designed specifically for Stage 4, advanced, rare, or heavily refractory cancers, this test scans massive portions of the genome to uncover hidden biological vulnerabilities, cross-tumor treatment targets, and global clinical trial matches.
₹7,00,000 — The Execution Bundle
Every Signature Complete CGP test automatically includes 3 months of full Blueprint Care (valued at ₹8,000/month) alongside an in-person multidisciplinary KCCIRC Tumour Board Review to transition raw data into an actionable real-world treatment roadmap.
- 523-Gene Comprehensive Panel: SNVs, InDels, CNVs, Fusions
- TMB & MSI: Immunotherapy eligibility biomarkers
- ctDNA Analysis: Real-time snapshot from a simple blood draw
- 3 Months of Blueprint Care: Execution bundled in
- KCCIRC Tumour Board: In-person multidisciplinary review
Beyond the organ. Beyond the standard.
Standard testing looks primarily at the organ where your cancer started. Signature Complete CGP goes deeper, analyzing complex genomic signatures critical for modern targeted therapies and next-generation immunotherapies.
Circulating Tumour DNA (ctDNA)
As cancer cells grow and turn over, they shed microscopic fragments of their DNA directly into your bloodstream. The extraction of ctDNA via a simple blood draw is fully recognized by international clinical guidelines — including ESMO's recommendations for advanced cancer — as a valid method to identify actionable mutations and direct targeted therapies without the need for invasive surgery.
Tumour Mutational Burden (TMB)
This metric measures the total number of mutations present within your cancer cells. Massive pan-tumour clinical studies have shown that a high mutational burden (TMB-H) is extensively linked to improved responses to modern checkpoint inhibitor immunotherapies across a wide range of solid tumours.
Microsatellite Instability (MSI)
MSI is a critical feature of how a cell's DNA repairs itself. Peer-reviewed research establishes MSI as a predictive biomarker for cancer immunotherapy, helping oncologists understand exactly if your immune system can be effectively stimulated to attack the tumour.
Tumour Fraction (TFx) Estimates
Your final report includes a precise Tumour Fraction estimate, calculating the exact proportion of the cell-free DNA (cfDNA) isolated in your blood sample that is actually tumour DNA. Accurately measuring this is emerging globally as a powerful, non-invasive biomarker to assess overall tumour burden and monitor disease progression over time.
Enterprise-grade computational power.
Behind every report is an enterprise-grade computational backbone engineered to find real-world answers where standard testing platforms fall short.
High-Throughput Sequencing
Testing utilizes Next Generation Sequencing (NGS) executed on high-throughput Illumina platforms to map out an ultra-deep genomic profile of your cancer without needing a tissue biopsy (or alongside one if tissue testing has already been done).
Illumina NGSGlobal Accreditation
Assays are extensively validated and performed in ISO 15189 / NABL accredited laboratories holding College of American Pathologists (CAP) accreditation — the absolute gold standard in global laboratory quality assurance.
CAP · ISO 15189 · NABLStandardized Interpretation
Analysis and reporting are undertaken strictly as per international consensus guidelines (ACMG / AMP / ASCO / CAP) using a CE-IVD certified mutation database for clinical variant interpretation and reporting.
ACMG · AMP · ASCO · CAPHuman Oncologist Sign-Off
We do not believe in automated, machine-generated emails. Every single sequencing portfolio is officially reviewed and signed off by an empanelled Medical Oncologist before release.
Medical Oncologist reviewedFrom blood draw to battle plan.
Sample collection kits are intended strictly for use by qualified phlebotomists and are not intended for patient self-testing or self-sampling.
Sample Collection
A specialized blood draw is completed by a phlebotomist at home or in clinic.
Advanced Sequencing
Cell-free DNA (cfDNA) is extracted and sequenced via deep NGS on Illumina platforms.
Computational Translation
Our engine filters noise, annotates complex variants, and maps targets to Indian drugs.
Medical Board & Delivery
A Medical Oncologist signs off, and your Navigator guides you through the roadmap.
Four potential outcomes.
When analyzing your ctDNA, the final report will yield one of four potential outcomes. Your doctor and Onkommon Navigator will explain what these mean in the context of your overall medical care.
Identify Actionable Genetic Changes
The test successfully isolates specific mutations linked directly to your cancer that can be targeted by specific drugs or clinical trials.
Changes of Uncertain Significance (VUS)
The test identifies genetic alterations whose significance is not yet fully understood by global medical literature. Our AI platform will deeply annotate these to see if they hold hidden potential.
No Reportable Changes Detected
The test did not find any of the specific mutations included in the 523-gene panel. (Note: This does not mean the cancer is gone; see limitations below).
Unable to Produce a Result
Occasionally, due to technical reasons or severe degradation of the blood sample during transport, the lab may be unable to extract sufficient DNA to sequence.
If actionable targets are found.
The Onkommon report architecture provides your oncologist with a structured, defensive war plan.
Therapies with Resistance
We isolate biological mutations that cause resistance to standard chemotherapies, protecting you from wasting precious time on toxic treatments that will not work.
Off-Label & Cross-Tumor Approvals
If your specific tumor driver mutation matches a targeted therapy approved for a different type of cancer, we compile the global literature and clinical evidence your doctor needs to justify accessing that drug.
Biosimilar Mapping for Cost Reduction
Biologics and targeted therapies can be cost-prohibitive. Our report automatically pairs expensive international branded therapies with clinically equivalent, CDSCO-approved biosimilars available in India to make your treatment financially sustainable.
Live Clinical Trial Matching
Your genomic profile is cross-referenced directly against active trial registries to support clinicians in identifying potential clinical trials for which you may be eligible.
523 genes. Ultra-deep sequencing.
The Signature Complete CGP panel provides ultra-deep sequencing across the following genes. Some genes are analyzed for multiple alteration types (e.g., FGFR1 is analyzed for SNVs, CNVs, and Fusions).
ABL1, ABL2, ACVR1, ACVR1B, AKT1, AKT2, AKT3, ALK, ALOX12B, ANKRD11, ANKRD26, APC, AR, ARAF, ARFRP1, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BBC3, BCL10, BCL2, BCL2L1, BCL2L11, BCL2L2, BCL6, BCOR, BCORL1, BCR, BIRC3, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTK, C11orf30, CALR, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD276, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CENPA, CHD2, CHD4, CHEK1, CHEK2, CIC, CREBBP, CRKL, CRLF2, CSF1R, CSF3R, CSNK1A1, CTCF, CTLA4, CTNNA1, CTNNB1, CUL3, CUX1, CXCR4, CYLD, DAXX, DCUN1D1, DDR2, DDX41, DHX15, DICER1, DIS3, DNAJB1, DNMT1, DNMT3A, DNMT3B, DOT1L, E2F3, EED, EGFL7, EGFR, EIF1AX, EIF4A2, EIF4E, EML4, EP300, EPCAM, EPHA3, EPHA5, EPHA7, EPHB1, ERBB2, ERBB3, ERBB4, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERG, ERRFI1, ESR1, ETS1, ETV1, ETV4, ETV5, ETV6, EWSR1, EZH2, FAM123B, FAM175A, FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FAS, FAT1, FBXW7, FGF1, FGF10, FGF14, FGF19, FGF2, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLI1, FLT1, FLT3, FLT4, FOXA1, FOXL2, FOXO1, FOXP1, FRS2, FUBP1, FYN, GABRA6, GATA1, GATA2, GATA3, GATA4, GATA6, GEN1, GID4, GLI1, GNA11, GNA13, GNAQ, GNAS, GPR124, GPS2, GREM1, GRIN2A, GRM3, GSK3B, H3F3A, H3F3B, H3F3C, HGF, HIST1H1C, HIST1H2BD, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, HIST1H3J, HIST2H3A, HIST2H3C, HIST2H3D, HIST3H3, HLAA, HLAB, HLAC, HNF1A, HNRNPK, HOXB13, HRAS, HSD3B1, HSP90AA1, ICOSLG, ID3, IDH1, IDH2, IFNGR1, IGF1, IGF1R, IGF2, IKBKE, IKZF1, IL10, IL7R, INHA, INHBA, INPP4A, INPP4B, INSR, IRF2, IRF4, IRS1, IRS2, JAK1, JAK2, JAK3, JUN, KAT6A, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIF5B, KIT, KLF4, KLHL6, KMT2B, KMT2C, KMT2D, KRAS, LAMP1, LATS1, LATS2, LMO1, LRP1B, LYN, LZTR1, MAGI2, MALT1, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAP3K14, MAP3K4, MAPK1, MAPK3, MAX, MCL1, MDC1, MDM2, MDM4, MED12, MEF2B, MEN1, MET, MGA, MITF, MLH1, MLL, MLLT3, MPL, MRE11A, MSH2, MSH3, MSH6, MST1, MST1R, MTOR, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, MYOD1, NAB2, NBN, NCOA3, NCOR1, NEGR1, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NKX3-1, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPM1, NRAS, NRG1, NSD1, NTRK1, NTRK2, NTRK3, NUP93, NUTM1, PAK1, PAK3, PAK7, PALB2, PARK2, PARP1, PAX3, PAX5, PAX7, PAX8, PBRM1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PDPK1, PGR, PHF6, PHOX2B, PIK3C2B, PIK3C2G, PIK3C3, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIM1, PLCG2, PLK2, PMAIP1, PMS1, PMS2, PNRC1, POLD1, POLE, PPARG, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PREX2, PRKAR1A, PRKCI, PRKDC, PRSS8, PTCH1, PTEN, PTPN11, PTPRD, PTPRS, PTPRT, QKI, RAB35, RAC1, RAD21, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RANBP2, RARA, RASA1, RB1, RBM10, RECQL4, REL, RET, RFWD2, RHEB, RHOA, RICTOR, RIT1, RNF43, ROS1, RPS6KA4, RPS6KB1, RPS6KB2, RPTOR, RUNX1, RUNX1T1, RYBP, SDHA, SDHAF2, SDHB, SDHC, SDHD, SETBP1, SETD2, SF3B1, SH2B3, SH2D1A, SHQ1, SLIT2, SLX4, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMARCD1, SMC1A, SMC3, SMO, SNCAIP, SOCS1, SOX10, SOX17, SOX2, SOX9, SPEN, SPOP, SPTA1, SRC, SRSF2, STAG1, STAG2, STAT3, STAT4, STAT5A, STAT5B, STK11, STK40, SUFU, SUZ12, SYK, TAF1, TBX3, TCEB1, TCF3, TCF7L2, TERC, TERT, TET1, TET2, TFE3, TFRC, TGFBR1, TGFBR2, TMEM127, TMPRSS2, TNFAIP3, TNFRSF14, TOP1, TOP2A, TP53, TP63, TRAF2, TRAF7, TSC1, TSC2, TSHR, U2AF1, VEGFA, VHL, VTCN1, WISP3, WT1, XIAP, XPO1, XRCC2, YAP1, YES1, ZBTB2, ZBTB7A, ZFHX3, ZNF217, ZNF703, ZRSR2.
Demystifying cancer genomics.
Want to learn more about ctDNA testing? Empower yourself with knowledge.
What is a Liquid Biopsy (ctDNA) and Why Do We Use It?
Medical Oncologist Dr. Christoph Oing explains how analysing ctDNA from a simple blood sample may reveal personalised, targeted treatment options for your cancer.
Video Placeholder · YouTubeCritical limitations & transparency.
Absolute transparency is the core of our clinical philosophy. Results must be interpreted by a qualified healthcare professional in conjunction with your full clinical history, other diagnostic test results, and relevant clinical guidelines.
DNA Shedding Variables
Not all cancers release enough DNA into the blood. Consequently, a normal or "no reportable alterations detected" result does not completely rule out the presence of active cancer or alternative tissue-level genetic changes.
Clonal Hematopoiesis Interference
Occasionally, detected genetic variations (mutations) can come from completely normal aging blood cells rather than shedding fragments of the actual solid tumour body.
Supportive Tooling
This genomic profile is an advanced clinical intelligence tool meant to support decision-making. The results are not intended to be used as the sole basis for treatment decisions, and further confirmatory testing may be required.
Access & Drug Availability
While the test may highlight genetic features linked to certain treatments or trials, it does not guarantee immediate access to a specific medicine, specific health insurance/PAP approval, or that a treatment will definitively work.
Regulatory Status
Onkommon genomic tests and testing methodologies comply with CDSCO and ICMR guidelines for in vitro diagnostic medical devices. They are intended for use by healthcare professionals for the qualitative identification of specific somatic variants in circulating tumour DNA (ctDNA).
Frequently Asked Questions
Everything you need to know about Signature Complete CGP.
Signature Complete CGP is a genomic (DNA-based) test designed to look for genetic changes in cancer using a simple blood sample. Tumours can release tiny fragments of DNA into the bloodstream, called circulating tumour DNA (ctDNA). By analysing this, we can understand the genetic features of a cancer without needing a tissue biopsy.
Not necessarily. While the test may heavily highlight genetic features linked to certain targeted treatments or clinical trials, it does not act as a prescription. Your oncologist makes the final treatment decision based on these results combined with your physical health.
Always discuss your results with your treating doctor or specialist. Additionally, your dedicated Onkommon Clinical Navigator will sit with you to explain what the report means in plain language and what logistical steps should be taken next.
If the test shows "no reportable changes," it means the specific 523 genes we tested did not show mutations. However, because some tumours do not shed enough DNA into the blood, this does not mean your cancer is gone. Your doctor will use standard scans to continue monitoring your health.